Last week the Supreme Court gave its decision in a long-running pharmaceutical patent dispute between Warner-Lambert and Generics. The court analysed patent insufficiency as a basis for invalidity and the infringement of Swiss-form claims.
Although most relevant to the drugs industry, this ruling will also be of interest to other patent-heavy sectors.
We discuss the analysis of insufficiency, and infringement on our sister blog Life Science Law.